CN118251221A - 用于减少肝脏体积的瑞司美替罗 - Google Patents

用于减少肝脏体积的瑞司美替罗 Download PDF

Info

Publication number
CN118251221A
CN118251221A CN202280075697.1A CN202280075697A CN118251221A CN 118251221 A CN118251221 A CN 118251221A CN 202280075697 A CN202280075697 A CN 202280075697A CN 118251221 A CN118251221 A CN 118251221A
Authority
CN
China
Prior art keywords
liver
less
prodrug
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280075697.1A
Other languages
English (en)
Chinese (zh)
Inventor
R·陶布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madrigal Pharmaceuticals Inc
Original Assignee
Madrigal Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madrigal Pharmaceuticals Inc filed Critical Madrigal Pharmaceuticals Inc
Publication of CN118251221A publication Critical patent/CN118251221A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280075697.1A 2021-09-27 2022-09-27 用于减少肝脏体积的瑞司美替罗 Pending CN118251221A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163248634P 2021-09-27 2021-09-27
US63/248,634 2021-09-27
PCT/US2022/044826 WO2023049491A1 (en) 2021-09-27 2022-09-27 Resmetirom for reducing liver volume

Publications (1)

Publication Number Publication Date
CN118251221A true CN118251221A (zh) 2024-06-25

Family

ID=83900064

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280075697.1A Pending CN118251221A (zh) 2021-09-27 2022-09-27 用于减少肝脏体积的瑞司美替罗

Country Status (13)

Country Link
US (2) US20240408102A1 (https=)
EP (2) EP4408428A1 (https=)
JP (1) JP2024536126A (https=)
KR (1) KR20240073926A (https=)
CN (1) CN118251221A (https=)
AR (1) AR127165A1 (https=)
AU (1) AU2022348966A1 (https=)
CA (1) CA3233319A1 (https=)
CL (1) CL2024000886A1 (https=)
IL (1) IL311670A (https=)
MX (1) MX2024003967A (https=)
TW (1) TW202337470A (https=)
WO (1) WO2023049491A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121443313A (zh) * 2023-06-08 2026-01-30 成都微芯药业有限公司 PPAR全激动剂联合THR-β激动剂在抗代谢相关疾病中的用途
WO2024263714A1 (en) * 2023-06-22 2024-12-26 Madrigal Pharmaceuticals, Inc. BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES
KR20260000642A (ko) * 2024-06-25 2026-01-05 연세대학교 산학협력단 Usp10 억제제를 유효성분으로 포함하는, 간섬유증 또는 간섬유증 관련 질환의 예방 또는 치료용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092872A1 (es) 2012-09-17 2015-05-06 Madrigal Pharmaceuticals Inc Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos
CA3111025C (en) * 2018-09-06 2023-10-31 Galmed Research And Development Ltd Combination therapy for the treatment of liver disease

Also Published As

Publication number Publication date
TW202337470A (zh) 2023-10-01
EP4408428A1 (en) 2024-08-07
JP2024536126A (ja) 2024-10-04
US20260069598A1 (en) 2026-03-12
IL311670A (en) 2024-05-01
WO2023049491A1 (en) 2023-03-30
AR127165A1 (es) 2023-12-27
CA3233319A1 (en) 2023-03-30
AU2022348966A1 (en) 2024-04-11
KR20240073926A (ko) 2024-05-27
EP4578499A3 (en) 2025-09-17
CL2024000886A1 (es) 2024-08-30
EP4578499A2 (en) 2025-07-02
MX2024003967A (es) 2024-06-03
US20240408102A1 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
CN118251221A (zh) 用于减少肝脏体积的瑞司美替罗
US10772865B2 (en) Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
EP4385571B1 (en) A lysyl oxidase-like 2 inhibitor for use in treating primary myelofibrosis
KR102412997B1 (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
US12589086B2 (en) Compositions and methods for the treatment of primary biliary cholangitis
WO2020206623A1 (en) Crystal forms
WO2024041596A1 (zh) 苯妥英钠作为线粒体自噬诱导剂的用途
CN115364224B (zh) Glut1抑制剂作为线粒体自噬诱导剂的用途
US20240423992A1 (en) Biomarkers for treating liver disorders with thr-b agonists and related uses
US20210030701A1 (en) Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis
WO2025078880A1 (en) Mitochondria-targeted antioxidants for use in the treatment of cell balloooning-associated diseases, such as non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash)
HK40128789A (en) Resmetirom for reducing liver volume
CN113166195A (zh) 在正在治疗高胆固醇相关疾病的患者中降低糖尿病风险的方法
JP7572007B2 (ja) ニコチンアミドモノヌクレオチド（ｎｍｎ）およびニコチンアミドリボシド（ｎｒ）の新規用途
WO2020199650A1 (zh) 依达拉奉在非酒精性脂肪肝炎治疗或预防中的应用
CN114401745A (zh) 包含fxr激动剂的治疗
CN111184706B (zh) 一种防治胆囊炎的活性药物及其用途
TW202019403A (zh) 包含6,8-雙-苄硫基-辛酸或其藥學上可接受的鹽的第一治療劑在製備治療胰臟癌之藥物上的用途
WO2019233473A1 (zh) 脂肪性肝病及其相关疾病的预防和治疗性药物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination